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Background: TNF-a mediated inflammation is thought to play a key role in the respiratory and systemic features
of Chronic Obstructive Pulmonary Disease. The aim of the present study was to replicate and extend recent
findings in Taiwanese and Caucasian populations of associations between COPD susceptibility and variants of the
TNFA gene in a Spanish cohort.
Methods: The 3 reported SNPs were complemented with nine tag single nucleotide polymorphisms (SNP) of the
TNFA and LTA genes and genotyped in 724 individuals (202 COPD patients, 90 smokers without COPD and 432
healthy controls). Pulmonary function parameters and serum inflammatory markers were also measured in COPD
patients.
Results: The TNFA rs1800630 (-863C/A) SNP was associated with a lower COPD susceptibility (ORadj = 0.50, 95% CI
= 0.33-0.77, p = 0.001). The -863A allele was also associated with less severe forms of the disease (GOLD stages I
and II) (ORadj = 0.303, 95%CI = 0.14-0.65, p = 0.014) and with lower scores of the BODE index (< 2) (ORadj = 0.40,
95%CI = 0.17-0.94, p = 0.037). Moreover, the -863A carrier genotype was associated with a better FEV1 percent
predicted (p = 0.004) and a lower BODE index (p = 0.003) over a 2 yrs follow-up period. None of the TNFA or LTA
gene variants correlated with the serum inflammatory markers in COPD patients (p > 0.05).
Conclusions: We replicated the previously reported association between the TNFA -863 SNP and COPD. TNFA
-863A allele may confer a protective effect to the susceptibility to the disease in the Spanish population.
Background
Tumour necrosis factor alpha (TNF-a) is critical in the
regulation of inflammation by inducing a cascade of
other inflammatory cytokines, chemokines, and other
growth factors [1]. The results of several in vitro and in
vivo investigations indicate that high-level generation of
TNF-a leads to an exacerbation of the inflammatory
and pro-oxidative responses that are important in the
pathogenesis of many diseases. TNF-a mediated inflam-
mation is thought to play a key role in both the respira-
tory and systemic features of Chronic Obstructive
Pulmonary Disease (COPD) [2].
Higher concentration of TNF-a has been reported in
induced sputum in stable COPD patients and during
exacerbations. This cytokine was also found increased in
bronchial biopsies and bronchoalveolar lavage fluid of
COPD patients when compared with control subjects
[3]. A meta-analysis study found higher circulating
TNF-a levels in COPD patients when compared to con-
trols [4] and these were also related with important
weigh loss in severe patients [5].
Genetic variation in the promoter region of TNFA
(chromosome 6p21) has been associated with different
phenotype expressions, an daw i d er a n g eo fa u t o i m -
mune, infectious, and oncologic diseases [2]. A common
G-to-A single nucleotide polymorphism (SNP) at posi-
tion -308 (rs1800629), directly affects gene regulation
and has been associated with increased transcriptional
activity of TNFA in various disorders [6,7]. This
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phenotypes, with contradictory results. It has also been
associated with chronic bronchitis and an increased risk
of airflow obstruction in Asian populations [8,9]. Most
studies in Caucasian populations could not demonstrate
this association [10-13]. Only two studies showed an
association of the -308 SNP and COPD, the first being a
large family study from the Boston early-onset COPD
study (2006) and the second performed by Gingo and
colleagues (2008) found an increased risk of the A allele
of being associated with the disease [14,15].
A 2010 study performed in Taiwanese individuals
identified TNF -863A (rs1800630) variant to be asso-
ciated less frequently with COPD [16].
The neighbouring gene, lymphotoxin alpha (LTA) has
also been related to alter TNF-a expression. TNF-a and
LT-a are proinflammatory cytokines coded for by the
TNFA and LTA genes, respectively, mediating a large
variety of inflammatory and immunostimulatory
responses. The +252 (A to G) SNP in the LTA gene has
received attention due to its supposed implication in
gene regulation [17] and reported associations with sev-
eral diseases [18,19]. Higher levels of TNF-a have been
reported to be associated with SNPs in the LTA gene
[20]. A case-control study performed on a Russian
population reported +252G allele to be associated with a
subgroup of severe COPD patients [21]. There is only
one study exploring the association of SNPs in both
genes and lung function in smokers with mild-to-mod-
erate airway obstruction [12].
The aim of the present study was to replicate recent
findings in Taiwanese and Caucasian populations of
associations between COPD susceptibility and variants
(rs1800629, rs361525 and rs1800630) of the TNFA gene
in a Spanish cohort. We further aimed to extend on
these findings by assessing whether variants/haplotypes
of the entire TNFA and LTA genes may influence
COPD susceptibility, severity and lung function decline
in a Spanish cohort.
Methods
Subjects
Caucasian individuals included in this study were
divided into three groups, COPD patients, smokers
without COPD and healthy controls. COPD outpatients
were recruited from a pulmonary clinic at the Hospital
Universitario N. S. de Candelaria (Canary Islands, Spain)
from August 2002 to July 2009. Patients with a wide
range of disease severity were included using the follow-
ing criteria: age > 40 years, smoking history > 10 pack-
years and a post-bronchodilator FEV1/FVC ratio < 0.70
measured 20 min after the administration of 400 mg of
inhaled albuterol. Pulmonary function tests were mea-
sured according to GOLD guidelines [22]. The arterial
oxygen tension (PaO2) was measured at rest. Severe
hypoxemia was defined by PaO2 values < 60 mmHg.
Exercise capacity was also tested using the best of two
6-min walking distance (6MWD) tests separated by at
least 30 min following the ATS recommendations [23].
The body mass index (BMI) was calculated as the
weight in kilograms divided by the square of the height
in meters. The BODE (Body Mass Index, Airflow
Obstruction, Dyspnea, Exercise Performance) Index was
calculated as previously described [24]. All patients were
clinically stable (no exacerbation for at least 2 months)
at the time of evaluation. Patients were excluded if they
had history of other diseases like asthma or bronchiecta-
sis. As a control group we included 432 individuals
without respiratory disease and no smoking history from
an ongoing general adult population cohort named CDC
project in the Canary Islands [25]. Finally, the third
group included 90 current smokers with a cumulative
smoking history of > 15 pack-years and normal lung
function (FEV1% pred > 0.80; FEV1/FVC > 0.70). In
order to minimize any possible effect of population
structure on our estimations, cases and controls were
recruited if they have at least two generations of Canar-
ian ancestry [26].
The Ethics Committee of Clinical Investigation of the
Hospital approved this study (approval N°36) and writ-
ten informed consents were obtained from all subjects.
SNPs selection and genotyping
We selected the haplotype-tagging SNPs in the TNFA
and LTA genes using the resequencing data of the Eur-
opean individuals from the SeattleSNPs database http://
pga.gs.washington.edu. A multimarker tagging algorithm
with criteria of r2 > 0.8 and minor allele frequency
(MAF) ≥ 0.1 were used with the Haploview program
(version 3.2) [27]. Eleven SNPs in the TNFA gene (Gen-
Bank, AY066019) and LTA gene (GenBank AY070490)
were chosen. TNFA -857, -376 and -238 SNPs
(rs1799724, rs1800750 and rs361525) were included in
the study because they had been reported as susceptibil-
ity locus in other diseases [28-30].
Venous blood was collected from each individual and
total genomic DNA was extracted using the commer-
cially available GFX Kit (GE Healthcare). All tSNPs
selected were genotyped using SNaPshot
® SNP Geno-
typing Assay (Applied Biosystems, Foster City, CA).
Genotyping was blind to case or control status of sam-
ples. A random 20% of the samples were genotyped in
duplicate for quality control. The concordance rate for
the duplicate samples was 100%. Moreover, as a confir-
mational method a random number of samples (patients
and control subjects) was genotyped by direct sequen-
cing on an ABI PRISM 310 Genetic Analyser (Applied
Biosystems). Samples not yielding the genotypes of all
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remained in the study (199 COPD cases).
Serum measurements
COPD patients’ serum was separated from whole blood
by centrifugation (3200 rpm) and aliquots were stored
at -80°C until laboratory analysis. Circulating levels of
IL-6, IL-8, IL-16, TNF-a,M C P - 1 ,M M P - 9 ,P A R Ca n d
VEGF were measured by ELISA (R&D System, Minnea-
polis) according to manufacter’s instructions. The detec-
tion limits were 0.7 pg/ml, 3.5, 6.2, 5.0, 156, 10, and 5.0,
respectively. The within-assay coefficient of variation for
all assays was less than 10%.
Statistical analysis
Demographic and main clinical data are presented as
percentage and mean ± SD. Differences among groups
were explored using Student t test, Mann-Whitney U
rank test, or Pearson c2 test as appropriate. To perform
the analysis we used the statistical package SPSS v17
(SPSS, Inc). Evaluation of the progression of the disease
of clinical and pulmonary function variables using the
SNPs as comparative factor was performed using a gen-
eral linear modelling for repeated measures (GLIM). For
analysis of severity, GOLD stage and BODE index were
dichotomised to a mild-to-moderate (GOLD stage I-II
and BODE < 2) and severe disease (GOLD stage III-IV
and BODE ≥ 3) (table 1). Allele and genotype distribu-
tion in the patients and control groups was compared
using contingency tables and c
2 test for independence.
Disequilibrium values, departures from Hardy-Weinberg
equilibrium and haplotype reconstruction from biallelic
polymorphisms, were calculated using the GENEPOP
v3.4, Haploview v3.2 and PHASE v2.1 software pro-
grammes [29-32] as appropriate. A generalized additive
model was first used to estimate the genotype relative
risks (OR and their 95% confidence intervals) for COPD
susceptibility. This was calculated by using SNPSTATS
[33]. The effective number of independent marker loci,
based on pairwise LD between genotyped SNPs for
populations independently, was used for adjustment for
multiple tests [34]. To test haplotype associations and
for checking for consistency of the inferred data, haplo-
types were reconstructed from the best average good-
ness-of-fit output of six PHASE 2.1 runs with 1,000
permutations [32]. Multivariate logistic regression analy-
sis was used to adjust for potential risk and confounding
factors (age, sex, pack-yrs of smoking). ANOVA was
performed to test the effect of the polymorphisms and
serum proteins levels. In every case, a two-sided p value
of < 0.05 was considered statistically significant.
Results
Table 1 summarizes the demographic data and baseline
characteristics of the study groups. Of the 202 stable
COPD patients (153 men and 49 women), 59% of
patients were in GOLD stages I-II and 41% in GOLD
stages III-IV. Similarly, of the 163 patients where the
BODE index was possible to calculate, 68% scored < 2
in the BODE index and 32% scored higher (BODE ≥ 3).
All SNPs conformed to HWE with the exception of
rs746868 (p < 0.05), which was then excluded from
Table 1 Demographic characteristics of COPD patients, smokers and healthy individuals included in the association
study
Variable Cases (n = 202) Smoking controls (n = 90) Healthy controls (n = 432) P-value
Gender (male %) 76 49 75 < 0.0001
Age (years)* 62 ± 10 48 ± 9 53 ± 8 < 0.0001
Smoking history(pack-yrs)
†* 63 ± 27 35 ± 18 __ < 0.0001
FEV1* 1.53 ± 0.7 3.06 ± 0.71 __ < 0.0001
FEV1 % pred* 56 ± 22 102 ± 15 __ < 0.0001
FVC % pred* 86 ± 23 108 ± 16 __ < 0.0001
FEV1/FVC* 52 ± 12 79 ± 6 __ < 0.0001
6MWD (m) * 490 ± 86 __ __
BMI (Kg/m
2)*2 7 ± 5 _ _ _ _
BODE index* 2 ± 0.7 __ __
BODE index < 2
‡ 111 __ __
BODE index ≥ 3
‡ 52 __ __
GOLD I-II
‡ 119 __ __
GOLD III-IV
‡ 83 __ __
*Data are presented as mean ± SD
† Number of packs of cigarettes smoked per day × number of years smoking
‡ Number of subjects in the two groups of GOLD and BODE index considered to analysis.
FEV1: forced expiratory volume in one second; FVC: forced expiratory volume; % pred: per cent predicted; 6MWD: six-min walk distance test; BMI: body mass
index.
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brium (LD) between the SNPs in the TNFA and LTA
genes are shown in Figure 1. Very strong levels of LD
can be observed between SNPs within both genes. SNP
-863C/A in the TNFA gene was significantly associated
with COPD susceptibility as previously reported [16].
The frequency of the -863 A carrier genotype was signif-
icantly lower in COPD patients when compared with
healthy controls yielding an odds ratio of 0.61 (95% CI
= 0.42-0.88, p = 0.008) under a dominant model of
inheritance (see Additional file 1). This result remained
significant after adjusting for possible confounding fac-
tors as age and gender (OR = 0.50, 95% CI = 0.33-0.77,
p = 0.001) in a multivariate analysis (table 2). The
-863A allele resulted associated with less severe forms
of the disease (GOLD stages I and II) when compared
with severe COPD (GOLD stages III and IV) (ORadj =
0.303, 95%CI = 0.14-0.65, p = 0.014) (Figure 2). This
was consistent with the finding that the -863A allele
was significantly associated with patients who scored
lower in the BODE index (BODE < 2 vs. BODE ≥ 3;
ORadj = 0.40, 95%CI = 0.17-0.94, p = 0.037) (table 3).
Moreover, when analysing longitudinal clinical data of
the patients cohort, it resulted that the -863 SNP was
significantly associated with FEV1 percent predicted
(FEV1 % pred) (p = 0.004) and the BODE index (p =
0.003) over the 2 yrs follow-up period. The relation
found between these clinical parameters and the -863
genotype did not vary among these groups over time (p
> 0.05). In addition we found that FEV1 % pred and the
BODE index differed significantly in each one of three
moments included in the longitudinal analysis (table 4).
The obtained p-values were corrected for multiple test-
ing by the effective number of independent tests (8.85)
resulting in a significant association for allele A carriers
of the -863 SNP between the COPD cases and the
healthy controls group (adjusted p = 0.02). No signifi-
cant differences were found in COPD patients versus
smokers without the disease when analysing single
polymorphisms.
Global tests for haplotype were predicted from genoty-
pic data. These analyses revealed no differences in fre-
quency distribution between cases and the controls
groups: cases vs. smokers without the disease (p = 0.54)
and cases vs. healthy controls (p = 0.35) (table 5). When
we calculated haplotype relative effect to the most
Figure 1 Pairwise linkage disequilibrium between SNPs in the LTA and TNFA genes. Values provided in each box, were estimated as r
2
using Haploview 3.2. Dark grey regions depict strong LD (1.0), pale grey and white regions represent low LD.
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observed for the COPD patients sample. However, the
haplotype that contains the -863A allele was less fre-
quently observed in COPD cases than in healthy con-
trols individuals (non significant). In contrast, no
association was found with the previously reported
[14,15] SNPs rs1800629, rs361525 in TNF gene.
None of the TNFA or LTA gene variants analysed in
the present study resulted correlated with the circulating
IL-6, IL-8, IL-16, TNF-a,M C P - 1 ,M M P - 9 ,P A R Co r
Table 2 Association of SNPs in the LTA and TNFA genes with Chronic Obstructive Pulmonary Disease (COPD)
COPD cases vs. healthy control
Gene position SNP ID Seattle SNP database COPD cases MAF % Healthy controls MAF % ORadj (95% CI)
a P-value*
LTA
+49(C/A) rs2239704 Lt_2202 0.42 0.39 1.05 (0.79-1.4) 0.73
+252(A/G) rs909253 Lt_2374 0.30 0.30 1.08 (0.79-1.46) 0.63
+495(T/C) rs2229094 Lt_2619 0.31 0.33 0.83 (0.62-1.11) 0.2
+720(C/A) rs1041981 Lt_2847 0.29 0.30 1.05 (0.77-1.42) 0.78
TNFA
-863(C/A) rs1800630 Lt_4539 0.16 0.22 0.58 (0.41-0.83) 0.002
0.50 (0.33-0.77) 0.001**
-857(C/T) rs1799724 Lt_4545 0.09 0.09 1.41 (0.88-2.27) 0.16
-376(G/A) rs1800750 TNF_214 0.04 0.03 1.30 (0.64-2.66) 0.47
-308(G/A) rs1800629 TNF_282 0.15 0.15 0.97 (0.66-1.42) 0.87
-238(G/A) rs361525 TNF_352 0.06 0.06 1.25 (0.72-2.19) 0.43
+489(G/A) rs180610 TNF_1078 0.09 0.09 1.42 (0.88-2.22) 0.15
Data are presented as MAF: minor allele frequency (%). ORadj: odds ratio; CI: confidence interval. *p values < 0.05. Age and gender were included in a
multivariate logistic regression analyses as potential confounding factors in an additive model. **p value from a dominant genetic model.
Figure 2 Frequency distribution of the TNFA -863 CC and CA+AA genotypes (dominant model) in three groups: healthy control
subjects, GOLD I-II and GOLD III-IV COPD patients.
Córdoba-Lanús et al. BMC Medical Genetics 2011, 12:132
http://www.biomedcentral.com/1471-2350/12/132
Page 5 of 9VEGF levels in serum of COPD patients (p > 0.05, data
not shown).
Discussion
Our objective was to replicate results from previous stu-
dies [14-16] showing association between TNF poly-
morphisms and COPD. The present study investigates
the association of TNFA and LTA genes polymorphisms
and COPD presence and severity including eleven SNPs
of two genes that cover most of their variability. The
most important finding of our research suggests that the
previously reported [16]TNFA -863A allele is less fre-
quent in COPD patients. The presence of this allele was
associated with a less severe form of the disease (GOLD
stages I-II) and with lower scores of the BODE index (<
2). Moreover, this association remained unchanged after
adjustment for confounding factors like age and gender,
suggesting a robust effect.
The most recent study, performed in Taiwanese indi-
viduals, found that the -863A allele was associated less
frequently with COPD, with an increased FEV1/FVC
ratio and higher BMI among heavy smokers [16].
Another two studies on COPD found an association of
the haplotype containing the -863A variant with a lower
risk for susceptibility to COPD, one performed on a
Greek population [35] and the second performed on a
Caucasian one [14]. Similarly, in our study the only
haplotype that contains the -863A allele also tended to
be less likely in COPD patients. This region of the
TNFA promoter seems to affect transcription factors
binding capacity. The variant -863 has been reported to
specifically reduce 10 fold the binding affinity of the
transcription nuclear factor (NF-B) specially the form
p-50-p50 [36]. Most of the inflammatory proteins that
are up regulated in airways of COPD patients are regu-
lated by the transcription nuclear factor NF-Bt h a ti s
activated in alveolar macrophages of COPD patients
[37]. The -863A allele has been reported associated with
elevated TNF-a production by peripheral blood mono-
nuclear cells stimulated with concavalin A [38] while
others have associated this variant with reduced circulat-
ing levels of the cytokine [30,39]. In the present analysis
we could not find any relation between the SNP and
serum levels of TNF-a or any other inflammatory cyto-
kine measured.
One strength of the present study is that the associa-
tion found for the -863 SNP and FEV1 and BODE index
was also replicated when we explored the SNP associa-
tion in the three longitudinal clinical measures regis-
tered over the two years follow up period. This is the
first report of a case-control study that evaluated the
influence of gene variants on clinical and pulmonary
function longitudinal data in a cohort of COPD patients.
However, we did not replicate other previously
reported [14,15] associations of TNF polymorphisms
with the disease. Consistent with the majority of pre-
vious studies on Caucasians we found that the most stu-
died TNFA polymorphism (-308G/A) was not associated
with the presence of COPD in our sample. Only two
studies on Caucasians found significant association
between this SNP and COPD presence. The first was a
family based research from the Boston Early Onset
COPD study [15] that analysed 17 families but these
findings could not be replicated in a case control study
of later onset COPD patients. The second, a case-con-
trol study [14], found that the -308A allele had a higher
risk of being associated with COPD and was also
Table 3 Association tests of TNFA -863 C/A polymorphism
with COPD using multiple logistic regression analysis
BODE < 2 vs BODE ≥ 3
Included variable
a B
b ORadjusted 95% CI P-value
Dominant model
CA+ AA -9.17 0.400 0.17-0.94 0.037*
Age -0.023 0.977 0.94-1.02 0.256
Gender -0.162 0.850 0.38-1.94 0.699
Smoking (pack/yr) 1.571 4.811 0.99-1.02 0.305
aAge, gender and smoking history (pack/years) were included in the analyses
as confounding variables,
bRegression coefficient, OR: odds ratio; CI:
confidence interval, *p values < 0.05
Table 4 Longitudinal association of TNFA -863 polymorphism with pulmonary function and BODE index in COPD
patients
Parameter SNP Genotype Time P-value
†
baseline 1° year 2° year
FEV1 % pred CC 55.2 ± 20.1 52.1 ± 18.7 49.1 ± 19.7 0.004
CA+AA 64.9 ± 21.6 61.3 ± 19.4 62.0 ± 17.1
P-value 0.003 0.017 0.002
BODE CC 2 (0-5) 2(0-6) 2(0-6) 0.003
CA+AA 1 (0-4) 1(0-4) 1(0-4)
P-value 0.001 0.006 0.016
Data are presented as mean ± standard deviation (X ± SD) for FEV1 % pred and compared by T-Student test. The Bode index was summarized as median (5
th-
95
th pc) and compared by U-Mann Whitney test.
† Global p-value for GLIM test for repeated measures inter-groups.
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authors included as cases a subgroup of 11 individuals
with emphysema that did not met COPD diagnosis cri-
teria, and therefore this subgroup may have influence
the final results. In addition, a meta-analysis study per-
formed by Smolonska and colleagues [40] reported that
TNFA was found associated with COPD susceptibility
only in Asians.
In relation to other SNPs within the two genes ana-
lysed in previous studies, none of them were found asso-
ciated with COPD in the present study. This finding is
supported by the results obtained by the majority of
researches performed in Caucasian individuals
[10-15,40].
The present study has several limitations. Firstly, the
reduced sample size of the smoking control group with-
out the disease cannot exclude that the lack of associa-
tion found between cases and smokers without COPD
with the -863 SNP could be a false negative result due
to a type II error. The present analysis should be tested
in a large sample of smoking controls. Second, popula-
tion stratification should be addressed in this kind of
studies. Even though, it is known that human popula-
tions from Spain, including Canary Islands, are highly
homogenous in their genetic background [26], in order
to reduce the possibility of subtle population stratifica-
tion we included 100% Canarian individuals in our con-
trol groups (smokers and non-smokers) with at least
two generations of ancestors from the islands. And
third, we have not find correlation between the genetic
variants analysed and the functional aspects of the pro-
gression of the disease probably due to the short obser-
vational period of our study. Mayor long-term
longitudinal studies are needed in order to confirm the
relationships of certain factors with clinical and func-
tional variables of the disease.
We have found that COPD patients with the variant
-863A presented better lung function (GOLD stages I-II).
The -863A allele may be conferring a protective effect on
the progression of the disease, which could be explained
by the fact that COPD patients progress in different man-
ner along time. It has been hypothesized that the disease
progression could be represented by three steps suggest-
ing that, in most smokers the disease process will not
advance if innate inflammation is minimized which situ-
ate individuals at step 1 or 2 of the model, which is com-
parable to smokers with normal lung function or COPD
patients at GOLD stage I and II respectively [41]. This
may be the consequence of a genetic background that
protects smokers in progressing to severe forms of the
disease as it is shown by our results.
Conclusion
O u rd a t ac o n f i r map r e v i o u ss t u d yw h e r et h em i n o r
allele of SNP -863 in the TNFA gene was associated
with a reduced risk of COPD. Our findings also suggest
that the-863A allele is associated with less severe forms
of the disease. No association was observed for other
SNPs in TNF-LT genes and COPD. This is the first
study of TNFA and LTA gene polymorphisms in COPD
performed in a Spanish Population.
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Additional file 1: Table 6. Genotype frequency distribution of the
LTA and TNFA genes SNPs in COPD patients, healthy control and
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Table 5 Haplotype frequency of the LTA and TNFA genes SNPs in COPD patients vs. Healthy control individuals
Haplotypes* Total freq. Healthy controls n = 432 COPD cases n = 199 ORadj (95%CI)ª p-value
1 AATCCCGGGG 0.2827 0.2806 0.2982 1.00
2 C A C C A C G G G G 0.1703 0.1815 0.1461 0.70 (0.45 - 1.08) 0.11
3 C G T A C C G A G G 0.1311 0.1328 0.1220 1.03 (0.64 - 1.66) 0.90
4 CGTACCGGGG 0.1268 0.1280 0.1257 1.09 (0.67 - 1.78) 0.72
5 CACCCCGGGG 0.0806 0.0723 0.0944 1.27 (0.72 - 2.23) 0.40
6 AATCCTGGGA 0.0762 0.0749 0.0781 1.33 (0.76 - 2.35) 0.32
7 C A C C C C A G A G 0.0251 0.0205 0.0327 1.74 (0.75 - 4.00) 0.19
8 C A C C C C G G A G 0.0202 0.0196 0.0212 1.54 (0.59 - 4.02) 0.38
9 CATCCCGGGG 0.0165 0.0177 0.0139 1.59 (0.56 - 4.48) 0.38
10 Rare 0.0703
*Haplotypes: LT+49, LT+252, LT+495, LT+720, TNF-863, TNF-857, TNF-376, TNF-308, TNF-238, TNF+489.
ª ORadj: odds ratio adjusted by age and gender; CI: confidence interval.
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